Valuation: Tyra Biosciences, Inc.

Market Cap 1.51B 1.3B 1.22B 1.11B 2.09B 144B 2.13B 14.35B 5.61B 72.27B 5.67B 5.54B 240B P/E 2026 *
-9.38x
P/E 2027 * -8.53x
Enterprise Value 1.02B 880M 827M 752M 1.41B 97.4B 1.44B 9.69B 3.79B 48.78B 3.82B 3.74B 162B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.15%
Yield 2026 *
-
Yield 2027 * -
1 day+1.08%
1 week-4.60%
Current month-20.67%
1 month-21.90%
3 months-31.72%
6 months-9.65%
Current year-3.80%
1 week 24.61
Extreme 24.61
26.8
1 month 24.61
Extreme 24.61
33.72
Current year 24.61
Extreme 24.61
40.65
1 year 9.96
Extreme 9.96
40.65
3 years 6.42
Extreme 6.42
40.65
5 years 4.93
Extreme 4.93
40.65
10 years 4.93
Extreme 4.93
40.65
Manager TitleAgeSince
Chief Operating Officer 51 2018-10-31
Chief Executive Officer 46 2018-10-31
Director of Finance/CFO 69 2022-12-31
Director TitleAgeSince
Chairman 58 2019-02-28
Director/Board Member 46 2018-08-01
Director/Board Member 40 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
2/12/26 Sell

Founder

8,000 0.0150%
1/12/26 Sell

Founder

8,000 0.0150%
12/19/25
Alta Partners Management Co. LP
SellCompany 10,000 0.0187%
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%-4.60%+135.69%+63.16% 1.51B
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average -0.21%+1.29%+61.05%+191.36% 26.52B
Weighted average by Cap. -1.08%+0.53%+50.72%+164.41%

Financials

2026 *2027 *
Net sales - -
Net income -178M -153M -144M -131M -247M -16.99B -251M -1.69B -661M -8.51B -667M -653M -28.27B -212M -183M -172M -156M -294M -20.24B -299M -2.01B -787M -10.14B -795M -777M -33.68B
Net Debt -491M -424M -398M -362M -681M -46.91B -692M -4.67B -1.82B -23.49B -1.84B -1.8B -78.07B -323M -279M -262M -238M -448M -30.88B -455M -3.07B -1.2B -15.46B -1.21B -1.19B -51.38B
Logo Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).
Employees
87
Date Price Change Volume
26-08-14 US$25.29 +1.08% 420,526
26-08-13 US$25.02 -1.11% 528,378
26-08-12 US$25.30 +0.48% 478,347
26-08-11 US$25.18 -4.08% 730,128
26-08-10 US$26.25 -0.98% 439,504
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
25.29USD
Average target price
50.82USD
Spread / Average Target
+100.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TYRA Stock